<?xml version='1.0' encoding='utf-8'?>
<document id="18576910"><sentence text="Possible antiretroviral therapy-warfarin drug interaction." /><sentence text="Highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) has resulted in significant morbidity and mortality reductions" /><sentence text=" Lifelong antiretroviral therapy must be incorporated into each patient's medical regimen" /><sentence text=" Patients with HIV may also have simultaneous chronic medical conditions, resulting in the possibility of complex drug-drug interactions" /><sentence text=" We report a possible drug-drug interaction between HAART and warfarin in two patients, as assessed by the Naranjo adverse drug reaction probability scale and the Drug Interaction probability scale" /><sentence text=" Both patients' pharmacotherapy regimens included a nonnucleoside reverse transcriptase inhibitor (NNRTI), nevirapine, or a protease inhibitor, nelfinavir or lopinavir-ritonavir, and two nucleoside analogs"><entity charOffset="107-117" id="DDI-PubMed.18576910.s6.e0" text="nevirapine" /><entity charOffset="144-154" id="DDI-PubMed.18576910.s6.e1" text="nelfinavir" /><entity charOffset="168-177" id="DDI-PubMed.18576910.s6.e2" text="ritonavir" /><entity charOffset="187-197" id="DDI-PubMed.18576910.s6.e3" text="nucleoside" /><pair ddi="false" e1="DDI-PubMed.18576910.s6.e0" e2="DDI-PubMed.18576910.s6.e0" /><pair ddi="false" e1="DDI-PubMed.18576910.s6.e0" e2="DDI-PubMed.18576910.s6.e1" /><pair ddi="false" e1="DDI-PubMed.18576910.s6.e0" e2="DDI-PubMed.18576910.s6.e2" /><pair ddi="false" e1="DDI-PubMed.18576910.s6.e0" e2="DDI-PubMed.18576910.s6.e3" /><pair ddi="false" e1="DDI-PubMed.18576910.s6.e1" e2="DDI-PubMed.18576910.s6.e1" /><pair ddi="false" e1="DDI-PubMed.18576910.s6.e1" e2="DDI-PubMed.18576910.s6.e2" /><pair ddi="false" e1="DDI-PubMed.18576910.s6.e1" e2="DDI-PubMed.18576910.s6.e3" /><pair ddi="false" e1="DDI-PubMed.18576910.s6.e2" e2="DDI-PubMed.18576910.s6.e2" /><pair ddi="false" e1="DDI-PubMed.18576910.s6.e2" e2="DDI-PubMed.18576910.s6.e3" /></sentence><sentence text=" In both patients, high warfarin doses were required to maintain therapeutic international normalized ratios (INRs)" /><sentence text=" Warfarin has two enantiomers, R-and S-warfarin, which are substrates primarily of cytochrome P450 (CYP) 3A4 (R-warfarin), CYP1A2 (R-warfarin), and CYP2C9 (S-warfarin)"><entity charOffset="1-9" id="DDI-PubMed.18576910.s8.e0" text="Warfarin" /><entity charOffset="131-141" id="DDI-PubMed.18576910.s8.e1" text="R-warfarin" /><entity charOffset="148-154" id="DDI-PubMed.18576910.s8.e2" text="CYP2C9" /><entity charOffset="156-166" id="DDI-PubMed.18576910.s8.e3" text="S-warfarin" /><pair ddi="false" e1="DDI-PubMed.18576910.s8.e0" e2="DDI-PubMed.18576910.s8.e0" /><pair ddi="false" e1="DDI-PubMed.18576910.s8.e0" e2="DDI-PubMed.18576910.s8.e1" /><pair ddi="false" e1="DDI-PubMed.18576910.s8.e0" e2="DDI-PubMed.18576910.s8.e2" /><pair ddi="false" e1="DDI-PubMed.18576910.s8.e0" e2="DDI-PubMed.18576910.s8.e3" /><pair ddi="false" e1="DDI-PubMed.18576910.s8.e1" e2="DDI-PubMed.18576910.s8.e1" /><pair ddi="false" e1="DDI-PubMed.18576910.s8.e1" e2="DDI-PubMed.18576910.s8.e2" /><pair ddi="false" e1="DDI-PubMed.18576910.s8.e1" e2="DDI-PubMed.18576910.s8.e3" /><pair ddi="false" e1="DDI-PubMed.18576910.s8.e2" e2="DDI-PubMed.18576910.s8.e2" /><pair ddi="false" e1="DDI-PubMed.18576910.s8.e2" e2="DDI-PubMed.18576910.s8.e3" /></sentence><sentence text=" Protease inhibitors and NNRTIs have variable effects on CYP: induction, inhibition, or mixed" /><sentence text=" The increased warfarin doses required in these two patients may have been caused by induction of CYP3A4 by nevirapine, CYP2C9 by nelfinavir, or CYP2C9 by lopinavir-ritonavir"><entity charOffset="108-118" id="DDI-PubMed.18576910.s10.e0" text="nevirapine" /><entity charOffset="120-126" id="DDI-PubMed.18576910.s10.e1" text="CYP2C9" /><entity charOffset="130-140" id="DDI-PubMed.18576910.s10.e2" text="nelfinavir" /><entity charOffset="145-151" id="DDI-PubMed.18576910.s10.e3" text="CYP2C9" /><entity charOffset="165-174" id="DDI-PubMed.18576910.s10.e4" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.18576910.s10.e0" e2="DDI-PubMed.18576910.s10.e0" /><pair ddi="false" e1="DDI-PubMed.18576910.s10.e0" e2="DDI-PubMed.18576910.s10.e1" /><pair ddi="false" e1="DDI-PubMed.18576910.s10.e0" e2="DDI-PubMed.18576910.s10.e2" /><pair ddi="false" e1="DDI-PubMed.18576910.s10.e0" e2="DDI-PubMed.18576910.s10.e3" /><pair ddi="false" e1="DDI-PubMed.18576910.s10.e0" e2="DDI-PubMed.18576910.s10.e4" /><pair ddi="false" e1="DDI-PubMed.18576910.s10.e1" e2="DDI-PubMed.18576910.s10.e1" /><pair ddi="false" e1="DDI-PubMed.18576910.s10.e1" e2="DDI-PubMed.18576910.s10.e2" /><pair ddi="false" e1="DDI-PubMed.18576910.s10.e1" e2="DDI-PubMed.18576910.s10.e3" /><pair ddi="false" e1="DDI-PubMed.18576910.s10.e1" e2="DDI-PubMed.18576910.s10.e4" /><pair ddi="false" e1="DDI-PubMed.18576910.s10.e2" e2="DDI-PubMed.18576910.s10.e2" /><pair ddi="false" e1="DDI-PubMed.18576910.s10.e2" e2="DDI-PubMed.18576910.s10.e3" /><pair ddi="false" e1="DDI-PubMed.18576910.s10.e2" e2="DDI-PubMed.18576910.s10.e4" /><pair ddi="false" e1="DDI-PubMed.18576910.s10.e3" e2="DDI-PubMed.18576910.s10.e3" /><pair ddi="false" e1="DDI-PubMed.18576910.s10.e3" e2="DDI-PubMed.18576910.s10.e4" /></sentence><sentence text=" Thus, practitioners should prudently monitor INRs in patients receiving warfarin with concomitant HAART that includes either a protease inhibitor or an NNRTI" /><sentence text="" /></document>